PBS and NPR for Southwest Florida
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

FDA Panel Favors Approval For Drug-Oozing Addiction Implant

WMFE

Federal health advisers recommended approval Tuesday for an experimental implant designed to treat patients recovering from heroin and painkiller addiction.

Despite shortcomings in company studies, a majority of Food and Drug Administration advisers said the implant offers important benefits not currently available. The drug-oozing device is intended to be a safer, more reliable approach to controlling cravings and withdrawal symptoms.

“Overall the data did have some problems,” said Dr. Thomas Grieger, of the Maryland Department of Health. “But I think clearly there was no evidence of significant risk with this agent and there is evidence of significant benefit and hopefully great promise.”

The advisers voted 12-5 in favor of the device from Braeburn Pharmaceuticals. The FDA is scheduled to make its formal decision by Feb. 27.

The matchstick-size implant, dubbed Probuphine, slowly releases a low dose of buprenorphine over six months. Currently buprenorphine is available as a pill or film that dissolves under the tongue. It is considered a safer, more palatable alternative to methadone, the decades-old standard for controlling opioid addiction. Opioids are a powerful family of drugs that mimic the opium poppy, including medications like oxycodone and illicit narcotics like heroin.

More than 2.5 million Americans are addicted to opioids, according to federal estimates. But less than half are receiving medication-based treatment to help control the problem.

Braeburn executives told panelists Tuesday that its implant could help reduce cases of relapse among chronic drug abusers. Many recovering addicts struggle to stick with their daily medication, putting them at risk of returning to illicit drug use and overdosing.

But panelists questioned whether Braeburn’s studies accurately predict Probuphine’s success. They cited shortcomings in the company’s research including missing urine samples from some study participants. Additionally, many patients received additional drug therapy to control their cravings and symptoms, clouding the picture of the implant’s performance.

 

Copyright 2020 WUSF Public Media - WUSF 89.7. To see more, visit .

The Associated Press is one of the largest and most trusted sources of independent newsgathering, supplying a steady stream of news to its members, international subscribers and commercial customers. AP is neither privately owned nor government-funded; instead, it's a not-for-profit news cooperative owned by its American newspaper and broadcast members.
Associated Press